Ainos, Inc. (NASDAQ: AIMD)

Sector: Healthcare Industry: Medical Devices CIK: 0001014763
Market Cap 5.00 Mn
P/B 0.50
P/E -0.33
P/S 44.22
ROIC (Qtr) -65.89
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 11.00 Mn
Debt/Equity (Qtr) 1.10
Add ratio to table...

About

Ainos, Inc., with ticker symbol AIMD, operates in the diversified healthcare industry, specifically focusing on the development of novel point-of-care testing (POCT) and therapeutics based on very low-dose interferon alpha (VELDONA) and synthetic RNA-driven preventative medicine. The company's product pipeline includes commercial-stage VELDONA Pet cytoprotein supplements, clinical-stage VELDONA human therapeutics, and telehealth-friendly POCTs powered by the AI Nose technology platform. Ainos' main business activities revolve around the development...

Read more

Investment thesis

Bull case

  • Strong cash position of 1.13M provides 1.94x coverage of other current liabilities 581356, indicating excellent liquidity.
  • Cash reserves of 1.13M provide robust 1.94x coverage of current liabilities 581356, indicating strong short-term solvency.
  • Cash reserves of 1.13M provide solid 1.07x coverage of other non-current liabilities 1.05M, indicating strong liquidity.
  • Cash reserves of 1.13M exceed inventory value of 166883 by 6.76x, indicating strong liquidity and inventory management.
  • Cash position of 1.13M represents healthy 0.99x of working capital 1.14M, demonstrating strong operational liquidity.

Bear case

  • Operating cash flow of (4.62M) barely covers its investment activities of 173, with a coverage ratio of -26727.80, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 173 provide weak support for R&D spending of 7.95M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (4.62M) shows concerning coverage of stock compensation expenses of 4.90M, with a -0.94 ratio indicating potential earnings quality issues.
  • Free cash flow of (4.66M) provides weak coverage of capital expenditures of 36998, with a -125.98 ratio suggesting additional external financing needs for growth initiatives.
  • Operating cash flow of (4.62M) provides minimal -5779.89x coverage of tax expenses of 800, suggesting potential tax planning inefficiencies or unsustainable tax positions.

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.65 2.13
EV to Cash from Ops. EV/CFO -3.20 2.75
EV to Debt EV to Debt 1.34 17.25
EV to EBIT EV/EBIT -1.04 2.89
EV to EBITDA EV/EBITDA -1.55 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF -3.17 29.36
EV to Market Cap EV to Market Cap 2.96 25.09
EV to Revenue EV/Rev 130.71 32.80
Price to Book Value [P/B] P/B 0.50 4.73
Price to Earnings [P/E] P/E -0.33 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Int. cover (Qtr) -19.79 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -567.83 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -78.12 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 9.03 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 5.20 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) 9.03 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) 7.30 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) 71.45 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) 26.28 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 165.20 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 1.94 1.80
Current Ratio Curr Ratio (Qtr) 2.96 4.18
Debt to Equity Ratio Debt/Equity (Qtr) 1.10 1.20
Interest Cover Ratio Int Coverage (Qtr) -19.79 196.93
Times Interest Earned Times Interest Earned (Qtr) -19.79 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -8,375.30 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) -12,594.61 -2,478.60
EBT Margin % EBT Margin % (Qtr) -13,231.00 -2,690.42
Gross Margin % Gross Margin % (Qtr) 82.70 30.80
Net Profit Margin % Net Margin % (Qtr) -13,231.70 -2,821.53